Huizhi Jiangbei-Ketou Group & Hua Xun Intellectual Property "Biomedicine Special" 12th Roadshow

From2018Year8Month15Since the first phase of the roadshow, the 12th phase of the roadshow has been achieved.“12”In ancient Greece, it represented perfection.,CompleteAnd hopefully we can continue“Perfect”. Here, I would like to thank the leaders and investors for their support for the activity, the project parties for their trust in the interaction, and the behind-the-scenes staff who silently supported them!

Next, let's take a look at the highlights of this activity:

Project1:VEGFR-2 and PDGFR-β Double Target Class 1.1 Innovative wAMD Eye Drops-Suzhou Ruiming New Drug Research and Development Co., Ltd.

Suzhou Ruiming New Drug focuses on the research and development of new therapeutic small molecule ophthalmic drugs. The current global ophthalmic drug market is increasing annually on average.19%However, the current ophthalmic drugs still have major defects. For example, mainstream ophthalmic drugs inject macromolecular antibodies into the fundus by injection, which has large side effects and high professional requirements for relevant operators. Suzhou Ruiming's drugs are all in the form of eye drops, which are simple and easy to operate with small side effects.

At present, the research of Ruiming in Suzhou mainly focuses on wet macular degeneration (AMD), diabetic maculopathy, optic nerve protection (glaucoma, sugar yellow, etc.) and open-angle glaucoma. Among them, eye drops developed for wet maculopathy and diabetic maculopathy have filled the current research gap and have reached the stage of clinical declaration and candidate compounds respectively. The two eye drops for optic nerve protection are the first drugs and have also been developed to the stage of candidate compounds. However, for open-angle glaucoma, it is an independent innovative drug and has developed a lead compound.

Project2:Based onInnovative Medical Device Industry Transformation of Biodegradable Medical Polyurethane Biomaterials-Jiangsu Rui Li Biological Materials Co., Ltd.

Representative projects for degradable medical polyurethane materials include long-lasting polyester soft tissue filler microspheres, which are expected to replacePMMAAnd L-lactic acid fillers for wrinkle removal, lip augmentation, nose augmentation, scar repair, etc., to solve the problem."Ebev" injection caused some of the clinical problems of immune response and even muscle death. Another representative project is degradable ureteral stents, which need to be placed after most kidney, ureter and other upper urinary tract operations.80%Irritant urination in patients with benign lesions with stents will cause pain and discomfort. However, the scaffolds modified by polylactic acid materials all failed, and the reason for the failure may be due to the inapplicability of the materials. At present, the stent made of polyurethane material has completed all pre-clinical evaluations and submitted.CFDAApply for clinical research and submit innovative medical devices at the same time. The successful research and development of this project will solve the persistent pain points of degradable ureteral stents and reduce the complications of stent implantation.

Project3:Since Replica New Drug Project and Screening Platform-Kay Replicator(Shenzhen) Co., Ltd.

Kay Replica is committed to the development of innovative drugs for anti-tumor and treatment of autoimmune diseases.ProjectIncludeEP4antagonist(KF-0210）、JAK3Inhibitors (KF-0229）、RETinhibitorsetc, the above itemsAll throughCROImplementation; In addition, it is establishedAHTSDrug Screening and Optimization Platform, the platformcan directly assess the affinity of small molecule compounds for target proteins(Kd），OneAHTSWorkstations can filter up150A drug store, equivalent25Ten thousand compounds, can effectively accelerate the development of new drugs.

ECXun is your bridge between China and the world, technology and market!

Relying on the platform of project and capital docking in the medical and health industry, ECON is committed to creating a more direct, pure and professional medical and health mutual aid ecosystem. With the vision of a win-win situation among production, investment and finance, it will alleviate the difficulties of financing and obtaining resources in early projects in the medical field, give the project side, investors and the park effective information to the maximum extent, and complete the effective docking of capital and projects.